NVIDIA and Eli Lilly both shattered expectations this quarter, but picking the better stock for the next decade means choosing between two very different growth machines at very different levels of risk.

Novo Nordisk took the stage at its own capital markets day and said something that sent its stock tumbling 7%, yet its closest rivals barely flinched. What the company revealed about its future tells investors exactly how much trouble the Ozempic empire may be in.

Eli Lilly stock gained after the FDA approved Inluriyo plus Verzenio on September 18, 2026. Quarterl

Eli Lilly demonstrates superior operating momentum, while Novo Nordisk offers lower expectations and higher cash returns. Learn why LLY and NVO are rated Hold.

Eli Lilly and Company (LLY) said Monday it has broken ground on a $6.5 billion manufacturing facilit

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) broke ground today in Houston, Texas, one of ten U.S. manufacturing sites — and fifth location to produce...

Eli Lilly and Co. stock closed at USD 1,152.62 on September 18, 2026, while new fair value and price

Korea Lilly marks World Volunteer Day with senior aid and community service Employees serve meals, haul briquettes, and pitch in across Seoul for World Volunteer Day

Eli Lilly has turned into one of the most closely watched stocks in global healthcare, and with that attention comes a simple question for investors. At around US$1,152.93 per share, is the current price in line with the cash flows that Lilly can plausibly generate over time? Over the past 5 years, Eli Lilly has delivered a very large total return of about 4.2x, which puts a lot of weight on whether its cash flows can keep supporting such a re-rating. Recent approvals and upgrades around...

Eli Lilly and Co. stock trades near USD 1,155 on September 18, 2026 as its market value tops USD 1 t